Condition

Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions16

Lead sponsors shown2

Clinical trials

2 shown

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerNCT03432741 · 2018-03-27

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionNCT01638533 · 2012-08-03

Common interventions

RomidepsinDRUG2 BelinostatDRUG1 CarfilzomibDRUG1 Copanlisib HydrochlorideDRUG1 DaratumumabBIOLOGICAL1 Fludeoxyglucose F-18DRUG1 Gemcitabine HydrochlorideDRUG1 Laboratory Biomarker AnalysisOTHER1 NivolumabBIOLOGICAL1 ObinutuzumabBIOLOGICAL1 PembrolizumabBIOLOGICAL1 Pharmacological StudyOTHER1 Positron Emission TomographyPROCEDURE1 RituximabBIOLOGICAL1 SalineOTHER1 TrastuzumabBIOLOGICAL1

Leading sponsors

Mayo Clinic1 National Cancer Institute (NCI)1

Trial status mix

COMPLETED1

TERMINATED1

Phase mix

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.